NCT06259058View on ClinicalTrials.gov

Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

December 1, 2027

Conditions

Pancreatic Cancer

Interventions

DRUG

Irinotecan liposome injection

50 mg/m² on Day 1 of a 14-day cycle

DRUG

Oxaliplatin

60 mg/m² on Day 1 of a 14-day cycle

DRUG

5-Fluorouracil

2400 mg/m² continuous IV infusion in 46 h

DRUG

Leucovorin

400 mg/m² on Day 1 of a 14-day cycle

RADIATION

SBRT

30Gy/5Fx

All Listed Sponsors

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT06259058 - Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter